EL7.AI
StocksMedium•16 November 2026•
1 min read

Akeso Stock Declines Following FDA Rejection of Lung Cancer Drug Application

Key Facts

1Akeso shares experienced a sharp decline following the US FDA's rejection of the company's lung cancer treatment license application.

Akeso shares experienced a sharp decline following the US FDA's rejection of the company's lung cancer treatment license application. Investing.com reported that the rejection creates a major regulatory hurdle and delays the potential commercialization of a key pipeline product.

The stock, traded under the ticker 9926.HK, closed at 82.3 dollars on November 13, 2026. During that session, the shares reached a high of 84.55 dollars and a low of 81.55 dollars.

Open on chart